Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoricoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 20/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.97 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoricoxib SCHEMBL28893910 | 1.00 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29366203 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29402456 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL30988052 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL321747 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL183950 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL322344 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL28319282 | 0.96 | PTGS2 (0.95) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655231-B2 | Etoricoxib solvates and preparation method thereof | TIANJIN UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20210300892-A1 | ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF | TIANJIN UNIVERSITY | 2021-09-30 | — | — | US | disclosed |
| CN-111410629-A | Etoricoxib solvate and preparation method thereof | 天津大学 | 2020-07-14 | — | — | CN | disclosed |
| EP-2714676-B1 | A PROCESS FOR THE PREPARATION OF POLYMORPHIC FORM I OF ETORICOXIB | FARMA GRS D O O (SI) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888231-B1 | PROCESS FOR PREPARATION OF CRYSTALLINE ETORICOXIB | GLENMARK PHARMACEUTICALS LTD (IN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2888231-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE ETORICOXIB | Glenmark Pharmaceuticals Limited (IN) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014041558-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE ETORICOXIB | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-03-20 | — | — | WO | disclosed |
| WO-2012163839-A1 | A PROCESS FOR THE PREPARATION OF POLYMORPHIC FORM I OF ETORICOXIB | FARMA GRS, D.O.O. (SI) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300892-A1 | ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF | ETV1, PTGES3, EIF4E | PTGS2 15/4885PTGS1 8/4885ABCC4 4072/4885 |
| US-11655231-B2 | Etoricoxib solvates and preparation method thereof | ETV1, PTGES3, EIF4E | PTGS2 15/4885PTGS1 8/4885ABCC4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.